Inflammotory diseases
- Geschlecht Beides
- Alter von 18 bis 55
- Rauchgewohnheiten Nicht
- BMI von 18 bis 30
- Berechnen Sie Ihren BMI hier
Study of a new compound that is being developed for the treatment chronic inflammatory diseases (such as rheumatoid arthritis)
Besonderheiten (auf Englisch)
- You are a healthy male or female.
- You are between 18 and 55 years old.
- You do not smoke.
- Your Body Mass Index (BMI) is between 18 and 30 kg/m2.
- You can only participate in this study if you have not participated in another study within 12 weeks prior to the first drug administration in this study.
- As a male you are only allowed to participate in this study if:
- You will use a condom and your fertile female partner uses an intrauterine device (including copper ones) or a hormonal contraceptive;
- or you were vasectomized;
- or your female partner is at least 12 months postmenopausal (without menstrual periods) or surgically sterilized;
- or you are completely abstinent (not sexually active) during the study in accordance with your lifestyle;
- or you are only sexual active with a male.
- As a female you are only allowed to participate in this study if:
- You have been postmenopausal and you have not menstruated for a period of 12 months before screening
- You were surgical sterilized (both ovaries or fallopian tubes have been removed, or removal of the uterus)
- To determine if you are eligible to participate in this study, you will undergo a medical screening in Groningen. This will take place within 6 weeks before the clinical start.
Vergütung (auf Englisch)
You will receive a gross compensation of €2.289,- for full participation in Group 2a or 2b..
Travel expenses will be reimbursed based on the distance traveled (€0.19 net per kilometer) with a minimum of €12 and a maximum of €160 (840 kilometers) per round trip, irrespective of the method of transportation.
Periode und Studie (auf Englisch)
For Group 2a and 2b, the study consists of 1 period in which you will stay in our research facility in Groningen for 14 days (13 nights).
Approximately 12 to 16 days after the last administration of the compound, a follow-up visit will take place.
Please note: These are the currently planned dates; however, these may be subject to change.
Group 2a |
14 days stay26 Oct 2020 up to and including 8 Nov 2020 |
follow-upby appointment |
Group 2b |
14 days stay7 Nov 2020 up to and including 20 Nov 2020 |
follow-upby appointment |
Group 2c |
14 days stay11 Nov 2020 up to and including 24 Nov 2020 |
follow-upby appointment |
Groep 2d |
14 days stay8 Dec 2020 up to and including 21 Dec 2020 |
follow-upby appointment |